Lowering triglycerides to modify cardiovascular risk: Will icosapent deliver?

Citations of this article
Mendeley users who have this article in their library.


Despite the clinical benefits of lowering levels of low-density lipoprotein cholesterol, many patients continue to experience cardiovascular events. This residual risk suggests that additional risk factors require aggressive modification to result in more effective prevention of cardiovascular disease. Hypertriglyceridemia has presented a considerable challenge with regard to understanding its role in the promotion of cardiovascular risk. Increasing evidence has established a clear causal role for elevated triglyceride levels in vascular risk. As a result, there is increasing interest in the development of specific therapeutic strategies that directly target hypertriglyceridemia. This has seen a resurgence in the use of omega-3 fatty acids for the therapeutic lowering of triglyceride levels. The role of these agents and other emerging strategies to reduce triglyceride levels in order to decrease vascular risk are reviewed.




Scherer, D. J., & Nicholls, S. J. (2015, March 25). Lowering triglycerides to modify cardiovascular risk: Will icosapent deliver? Vascular Health and Risk Management. Dove Medical Press Ltd. https://doi.org/10.2147/VHRM.S40134

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free